Shares of G1 THERAPEUTICS (NASDAQ:GTHX) have earned a consensus broker rating score of 1.25 (Strong Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and three have assigned a strong buy rating to the company.

Brokerages have set a 1 year consensus price objective of $29.67 for the company and are anticipating that the company will post ($0.56) earnings per share for the current quarter, according to Zacks. Zacks has also given G1 THERAPEUTICS an industry rank of 110 out of 265 based on the ratings given to related companies.

A number of brokerages have recently issued reports on GTHX. Wedbush began coverage on G1 THERAPEUTICS in a report on Monday, June 12th. They set an “outperform” rating and a $31.00 price target on the stock. Needham & Company LLC assumed coverage on G1 THERAPEUTICS in a report on Monday, June 12th. They issued a “buy” rating and a $34.00 target price on the stock. Cowen and Company assumed coverage on G1 THERAPEUTICS in a report on Monday, June 12th. They issued an “outperform” rating and a $31.00 target price on the stock. Finally, J P Morgan Chase & Co assumed coverage on G1 THERAPEUTICS in a report on Monday, June 12th. They issued an “overweight” rating and a $23.00 target price on the stock.

In other G1 THERAPEUTICS news, major shareholder Clay Thorp bought 133,333 shares of the business’s stock in a transaction that occurred on Monday, May 22nd. The stock was purchased at an average price of $15.00 per share, for a total transaction of $1,999,995.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Fredric N. Eshelman bought 300,000 shares of the business’s stock in a transaction that occurred on Monday, May 22nd. The shares were acquired at an average price of $15.00 per share, with a total value of $4,500,000.00. The disclosure for this purchase can be found here. Insiders bought 833,333 shares of company stock worth $12,499,995 in the last ninety days.

Hedge funds have recently added to or reduced their stakes in the company. RA Capital Management LLC acquired a new stake in G1 THERAPEUTICS during the second quarter valued at about $46,813,000. FMR LLC acquired a new stake in G1 THERAPEUTICS during the second quarter valued at about $34,093,000. Franklin Resources Inc. acquired a new stake in G1 THERAPEUTICS during the second quarter valued at about $10,651,000. Hillhouse Capital Management Ltd. acquired a new stake in G1 THERAPEUTICS during the second quarter valued at about $7,848,000. Finally, Laurion Capital Management LP acquired a new stake in G1 THERAPEUTICS during the second quarter valued at about $3,488,000. Hedge funds and other institutional investors own 5.16% of the company’s stock.

G1 THERAPEUTICS (NASDAQ:GTHX) traded up 9.735% during mid-day trading on Thursday, reaching $15.308. 69,512 shares of the company traded hands. The company’s 50-day moving average is $14.93 and its 200-day moving average is $16.07. G1 THERAPEUTICS has a 12-month low of $12.04 and a 12-month high of $20.60. The stock’s market capitalization is $22.66 million.

G1 THERAPEUTICS (NASDAQ:GTHX) last announced its quarterly earnings results on Wednesday, August 9th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by $0.48. Equities analysts predict that G1 THERAPEUTICS will post ($2.92) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Brokerages Anticipate G1 THERAPEUTICS (GTHX) to Post ($0.56) Earnings Per Share” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/08/17/brokerages-anticipate-g1-therapeutics-gthx-to-post-0-56-earnings-per-share.html.

About G1 THERAPEUTICS

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Get a free copy of the Zacks research report on G1 THERAPEUTICS (GTHX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related companies with MarketBeat.com's FREE daily email newsletter.